Division of Clinical Research

Office of the Vice President and Innovation

When the FDA learned of the novel coronavirus (COVID-19) and its potentially devastating effects, we acted swiftly to set the regulatory stage for drug and biologics manufacturers to develop products to treat this serious disease. To meet this urgent need, the FDA created the Coronavirus Treatment Acceleration Program (CTAP) to enable the FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) to leverage cross-agency scientific resources and expertise to bear on COVID-19 therapeutic development and review.

There are now more than 510 drug development programs in planning stages, and as of July 14th, the agency has reviewed more than 230 trials of potential therapies for COVID-19. 

To read more about the CTAP, click here.

Categories COVID-19
Tagged ,

Follow this blog